ArticleTranslational cancer research2025
Prognostic signature based on hypoxia and RNA methylation regulatory genes can improve the prognostic and recurrence prediction ability of low-grade glioma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accumulating evidence has demonstrated that both hypoxia and methylation are closely related to cancer progression. The high heterogeneity of low-grade gliomas (LGG) impedes the accurate prediction of patient prognosis. The prognostic value of the interaction between hypoxia and methylation regulation in LGG needs further study. Therefore, this study aims to develop a prognostic model for LGG by integrating hypoxia- and methylation-regulated genes to improve clinical outcome prediction. Methods: We used a robust bioinformatics framework to explore the role of hypoxia and methylation regulatory genes in the prognostic assessment of six independent cohorts (1,499 patients with LGG). We developed a prognostic classification model of LGG related to hypoxia and methylation regulation score. We then analyzed the relationship between hypoxia-methylation regulation-related scores (HMRs), genomic changes, and immune microenvironment, and evaluated the predictive performance of this model for immunotherapy and chemotherapy. Results: HMRs demonstrated excellent prognostic classification across the six independent cohorts. HMRs indicated significant associations with genomic instability and immune infiltration. Patients with LGG with high HMRs had more genetic mutations and structural variants and higher levels of immune infiltrations, and these patients responded better to immunotherapy. In LGG, IGFBP2 represents an independent prognostic factor and a potential therapeutic target, elevated IGFBP2 expression is linked to poor prognosis. Conclusions: The prognostic model based on hypoxia and methylation regulatory genes can accurately predict the prognosis and progression of LGG and guide immunotherapy and chemotherapy in patients with LGG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.